Plasma polyunsaturated fatty acid pattern in active inflammatory bowel disease

dc.contributor.authorEsteve i Comas, Mariacat
dc.contributor.authorRamírez, M.cat
dc.contributor.authorFernández Bañares, Fernandocat
dc.contributor.authorAbad Lacruz, Aguedacat
dc.contributor.authorGil, Ángelcat
dc.contributor.authorCabré i Gelada, Eduardcat
dc.contributor.authorGonzález-Huix Lladó, Ferrancat
dc.contributor.authorMoreno, J.cat
dc.contributor.authorHumbert Yagüe, Perecat
dc.contributor.authorGuilera Sardà, Magdacat
dc.contributor.authorBoix, J.cat
dc.contributor.authorGassull, Miquel Àngelcat
dc.date.accessioned2011-07-07T12:30:32Z
dc.date.available2011-07-07T12:30:32Z
dc.date.issued1992
dc.description.abstractPlasma fatty acid patterns were assessed by gas liquid chromatography in 73 patients with active inflammatory bowel disease and 107 healthy controls. The influence of the disease activity on fatty acid profile was also investigated. Plasma fatty acid patterns in patients with ulcerative colitis and Crohn's disease were similar. Plasma C18:3n3 and C22:6n3 were significantly higher in active ulcerative colitis (p = 0.0143 and p < 0.00001 respectively) and in Crohn's disease (p < 0.00001 for both) than in controls, whereas C20:3n6 was significantly lower in patients than in controls, both in ulcerative colitis (p = 0.0001) and in Crohn's disease (p = 0.0041). In more severe disease, plasma polyunsaturated fatty acid concentrations fell with a significant stepwise decrease in the desaturation index (p = 0.0031 in ulcerative colitis and p = 0.0355 in Crohn's disease). Even in patients with severe disease, however, plasma n3 fatty acids (C18:3n3 and C22:6n3) never fell below those of healthy controls. These findings suggest that in active inflammatory bowel disease, an increased biosynthesis might coexist with an increased consumption of polyunsaturated fatty acids. These observations may be of relevance in the pathogenesis of the disease as polyunsaturated fatty acids are involved in tissue eicosanoid synthesis and cellular membrane function, including that of immunocompetent cells. These results also question the rationale of using n3 polyunsaturated fatty acids in the treatment of inflammatory bowel disease.
dc.format.extent5 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec160741
dc.identifier.issn0017-5749
dc.identifier.pmid1446861
dc.identifier.urihttps://hdl.handle.net/2445/18657
dc.language.isoengeng
dc.publisherBMJ Groupeng
dc.relation.isformatofReproducció digital del document publicat a: http://dx.doi.org/10.1136/gut.33.10.1365cat
dc.relation.ispartofGut, 1992, vol. 33, núm. 10, p. 1365-1369
dc.relation.urihttp://dx.doi.org/10.1136/gut.33.10.1365
dc.rights(c) BMJ Publishing Group Ltd and British Society of Gastroenterology, 1992
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationMalalties inflamatòries intestinalscat
dc.subject.classificationÀcids grassos insaturatscat
dc.subject.otherInflammatory bowel diseaseseng
dc.subject.otherUnsaturated fatty acidseng
dc.titlePlasma polyunsaturated fatty acid pattern in active inflammatory bowel diseaseeng
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
160741.pdf
Mida:
1.09 MB
Format:
Adobe Portable Document Format